CV Sciences (OTCMKTS:CVSI) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.
Insider & Institutional Ownership
0.1% of CV Sciences shares are held by institutional investors. Comparatively, 31.9% of Natural Alternatives International shares are held by institutional investors. 10.1% of CV Sciences shares are held by insiders. Comparatively, 28.0% of Natural Alternatives International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent recommendations for CV Sciences and Natural Alternatives International, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Natural Alternatives International||0||0||0||0||N/A|
CV Sciences presently has a consensus price target of $8.00, suggesting a potential upside of 35.82%. Given CV Sciences’ higher possible upside, equities analysts plainly believe CV Sciences is more favorable than Natural Alternatives International.
This table compares CV Sciences and Natural Alternatives International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Natural Alternatives International||6.74%||13.63%||10.64%|
Risk and Volatility
CV Sciences has a beta of -0.72, indicating that its stock price is 172% less volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500.
Valuation and Earnings
This table compares CV Sciences and Natural Alternatives International’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CV Sciences||$48.24 million||11.80||$10.00 million||$0.09||65.44|
|Natural Alternatives International||$132.44 million||0.69||$5.05 million||N/A||N/A|
CV Sciences has higher earnings, but lower revenue than Natural Alternatives International.
CV Sciences beats Natural Alternatives International on 8 of the 12 factors compared between the two stocks.
CV Sciences Company Profile
CV Sciences, Inc. operates as a life science company. It operates through two segments, Specialty Pharmaceuticals and Consumer Products. The company focuses on developing and commercializing prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company also engages in the development, manufacture, marketing, and sale of consumer products containing plant-based CBD under the PlusCBD Oil name in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.
Natural Alternatives International Company Profile
Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States and internationally. It operates through two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. The company offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. It also provides strategic partnering services, such as customized product formulation, clinical studies, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, packaging and delivery system design, and regulatory review. In addition, the company sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. It manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. The company's private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. Natural Alternatives International, Inc. was founded in 1980 and is headquartered in Carlsbad, California.
Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.